Shares of Beta Bionics, Inc. (NASDAQ: BBNX) surged 6.07% in after-hours trading on Tuesday following the company's release of impressive second-quarter 2025 financial results and an upward revision of its full-year guidance.
The diabetes management solutions provider reported a 54% year-over-year increase in net sales, reaching $23.2 million for Q2 2025. This growth was driven by a 31% rise in the Durable Medical Equipment (DME) channel and a remarkable 498% surge in the Pharmacy Benefit Plan (PBP) channel. Beta Bionics also announced a significant increase in new patient starts, up 57% to 4,934 compared to the same period last year.
In light of these strong results, Beta Bionics raised its full-year 2025 revenue guidance to between $88 million and $93 million, up from the previous forecast of $82 million to $87 million. The company also improved its gross margin outlook for the year to 52%-55%. These positive developments, coupled with the expanding market penetration of its iLet Bionic Pancreas system, appear to have fueled investor optimism, resulting in the after-hours stock price surge.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.